Symptom Clusters and Biomarkers in COPD

Slideshow

The CASCADE study found the biomarker of inflammation CRP associated with higher COPD symptom burden.

Symptom burden in COPD is high and also heterogeneous, with patients experiencing different patterns of the same symptoms, ie, dyspnea, fatigue, depression. There is some evidence to suggest that disparities in symptom experience may be related to the individual ability to respond to stress, physical and psychological, through changes in pro- and anti-inflammatory cytokines.The current study is a descriptive analysis of data from the The COPD Activity: Serotonin Transporter, Cytokines and Depression (CASCADE) cohort that is following COPD patients to better understand the biological causes and functional consequences of depression.

Related Content
Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD / image credit courtesy of Upstream Bio

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD

Grace Halsey
July 11th 2025
Article

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

/ image credit ©alesmunt/stock.adobe.com

Sanofi, Regeneron's IL-33 mAb Misses Primary Endpoint in Late-Stage COPD Trial

Grace Halsey
May 30th 2025
Article

Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.

Dupilumab Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study / image courtesy of ResearchGate

Dupilumab for Severe COPD Shows Efficacy, Tolerability, Patient Satisfaction in New Real-World Study

Grace Halsey
May 27th 2025
Article

Dupilumab significantly reduced COPD exacerbations and received high satisfaction ratings from patients with severe disease and Th2 inflammation.

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype / image credit ©Waldenmarus/stock.adobe.com

Mepolizumab Approved as First Biologic to Treat COPD with Eosinophilic Phenotype

Grace Halsey
May 23rd 2025
Article

Mepolizumab, an IL-5 inhibitor targeting Th2 inflammation characterized by elevate serum eosinophil count, fills a treatment gap for ~70% of adults with uncontrolled COPD.

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD / image credit ©cpt88studio/stock.adobe.com

Machine Learning Model Effectively Predicts Depression Risk in Adults with COPD

Grace Halsey
May 7th 2025
Article

The model demonstrated 70.63% accuracy for predicting depression, a common comorbidity seen in COPD and one that increases risk for negative outcomes.

AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Asthma Trials / image credit Alberto Papi, MD, PhD Ferarra University Italy

AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Trials of Uncontrolled Asthma

Grace Halsey
May 2nd 2025
Article

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

© 2025 MJH Life Sciences

All rights reserved.